: City-based drug-maker Laurus Labs Tuesday said it sold the US Food and Drug Administration-approved tenofovir disoproxil fumarate (TDF), used to treat hepatitis B virus, to CASI Pharmaceuticals Inc, USA.
Discussions were on to allow Laurus to continue to manufacture and market the TDF in the US and to potentially supply abbreviated new drug application (ANDA) to China, a press release said here.
Founder and chief executive officer of Laurus Lab Satyanarayana Chava said in the release that the transfer of TDF ANDA for its use in China enhances the strategic focus of the company to leverage on development and manufacturing capabilities in the markets where its presence was not strong.
Partnering with CASI Pharmaceuticals would enable Laurus Labs monetise its assets in China while building a robust pipeline and commercialise quality drugs in other markets, he said in the release.
Disclaimer: No Business Standard Journalist was involved in creation of this content